Back to Journals » OncoTargets and Therapy » Volume 12

Polydatin exerts anti-tumor effects against renal cell carcinoma cells via induction of caspase-dependent apoptosis and inhibition of the PI3K/Akt pathway [Retraction]

Authors Jin YL, Xin LM, Zhou CC, Ren Y

Received 21 May 2019

Accepted for publication 21 May 2019

Published 4 June 2019 Volume 2019:12 Pages 4321—4322

DOI https://doi.org/10.2147/OTT.S216516


Jin Y-L, Xin L-M, Zhou C-C, Ren Y. Onco Targets Ther. 2018;11:8185–8195.

The Editor-in-chief and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised about the possibility of image manipulation in the published article. The alleged image manipulation relates to:

● Figure 2B 786-O 80 μM and Caki-1 80 μM
● Figure 4A Bcl-xl 786-O and Caki-1.

The authors provided the raw data for the requested images; however, the Editor found the provided images were unsatisfactory and doubts were raised about the accuracy of several other figures used in the article. The Editor determined the findings and conclusions presented in the study were no longer supported. The authors institution was contacted for comment but no response was received.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]